GeriQBank · Paper IV · Q6
CHA2DS2-VASc Score — Use and Clinical Significance
- Chapter
- Cardiology
- Years asked
- Not recorded in the source
- Frequency
- Set 1× in Paper IV (2009–2025)
As set in the university paper
CHADS2-VASc score — what is it used in and what is its clinical significance?
Paper IV · Cardiovascular Medicine · asked ×1 · 7-mark note · see in paper list
Answer framework
- Purpose — annual stroke risk in non-valvular AF; refinement of CHADS2; decision-making
- Components and the maximum of 9
- Clinical application — thresholds for men and women; age ≥75; annual reassessment
- Wider uses
- Limitations — no bleeding risk; omitted geriatric factors; modest discrimination
- Recent updates — alternative scores and risk-based decisions; risk modifiers; CHA2DS2-VA; up-scoring; biomarker scores
An exam answer plan drawn from the detailed answer below. Use it to attempt the question first.
Detailed answer
Pro · free in betaAttempt it firstOutline your answer as a 7-mark note before revealing it — definition, causes, evaluation, management and the geriatric angle.Reveal answer
Short revision answer
- CHA2DS2-VASc estimates the annual risk of ischaemic stroke and systemic embolism in non-valvular AF. It refined CHADS2 (which labelled too many patients low risk) and is used to weigh stroke reduction against bleeding.
- Points: Congestive heart failure or LV dysfunction 1; Hypertension 1; Age ≥75 2; Diabetes 1; Stroke/TIA/thromboembolism 2; Vascular disease (MI, PAD, aortic plaque) 1; Age 65–74 1; Sex category (female) 1. The maximum is 9, not 10, because age scores 0, 1 or 2 — never both bands.
- ≥2 in men or ≥3 in women — anticoagulate (Class I); 1 in men or 2 in women — consider after shared decision-making; 0 in men or 1 in women — no antithrombotic needed.
- Age ≥75 alone scores 2, so every older person with AF qualifies for anticoagulation unless contraindicated — the key geriatric point. Reassess at least annually as risk factors accumulate.
- Also used for device-detected atrial high-rate episodes, LAA occlusion eligibility and peri-procedural decisions.
- Limitations: no bleeding risk (pair it with HAS-BLED, ORBIT, ATRIA or ABC); omits renal function, frailty, anaemia, cognition and AF burden; modest discrimination (c-statistic ~0.6) in cohorts with few very old people; poor discrimination among the elderly, almost all of whom score ≥2.
- Updates: the 2023 ACC/AHA/ACCP/HRS guideline accepts ATRIA or GARFIELD-AF, decides on annual event rate (≥2% per year = Class 1) and adds risk modifiers (AF burden, BP control) below 2%. The 2024 ESC guideline uses CHA2DS2-VA (maximum 8), dropping sex because women's excess risk appears only with other factors. Lower ACC/AHA hypertension thresholds "up-score" patients (JAMA Cardiology 2023); the biomarker ABC stroke score (NT-proBNP, hs-cTnT) beats CHA2DS2-VASc in trials but adds little in real-world older people.
Condensed by GeriClinics from the detailed answer below, with no new facts added.
15–20 High-Yield Points
PURPOSE
CHA2DS2-VASc is a clinical risk-stratification score that estimates the annual risk of ischaemic stroke and systemic embolism in patients with non-valvular atrial fibrillation.
It was developed to refine the earlier CHADS2 score, which classified too many patients as “low risk” and missed those who would benefit from anticoagulation.
Its purpose is decision-making — it balances the reduction in stroke risk against the increased risk of bleeding from anticoagulation.
COMPONENTS (MAXIMUM SCORE 9)
C — Congestive cardiac failure (or LV dysfunction): 1 point
H — Hypertension: 1 point
A2 — Age ≥75 years: 2 points
D — Diabetes mellitus: 1 point
S2 — Stroke / TIA / thromboembolism: 2 points
V — Vascular disease (prior MI, peripheral arterial disease, or aortic plaque): 1 point 10. A — Age 65–74 years: 1 point
Sc — Sex category (female): 1 point
The maximum score is 9, not 10, because age can score only 0, 1 or 2 — it cannot count in both age bands.
CLINICAL APPLICATION
Score ≥2 in men or ≥3 in women — oral anticoagulation is recommended (Class I).
Score of 1 in men or 2 in women — anticoagulation should be considered, after shared decision-making.
Score 0 in men or 1 in women (female sex alone) — no antithrombotic therapy is required.
Age ≥75 alone gives 2 points, so every older person with AF qualifies for anticoagulation unless contraindicated. This is the single most important geriatric implication of the score.
The score should be reassessed at least annually, because risk factors accumulate dynamically with ageing.
WIDER USES AND LIMITATIONS
The score is also used in device-detected atrial high-rate episodes, to guide LAA occlusion eligibility, and to inform peri-procedural anticoagulation decisions.
Limitation — it does not include bleeding risk, so it must always be paired with a bleeding score such as HAS-BLED, ORBIT, ATRIA or ABC.
Limitation — it omits renal impairment, frailty, anaemia, cognitive status, and AF burden, all highly relevant in geriatric practice.
Limitation — it has modest discriminatory power (c-statistic ~0.6) and was validated in populations under-representing the very old.
Limitation — because age contributes so heavily, the score has poor discrimination within the elderly population, where almost everyone scores ≥2.
Current Practice Update
Textbook position (Pathy’s 6th ed.) Current evidence (2023–2026)
CHA2DS2-VASc is the single recommended score The 2023 ACC/AHA AF Guideline endorses CHA2DS2-VASc, ATRIA, or GARFIELD-AF, allowing flexibility Decision based on the score threshold Decision now based on estimated annual event rate — ≥2% per year is Class 1 Female sex scores 1 point as a risk factor Female sex is now a risk modifier; the 2024 ESC guideline uses CHA2DS2-VA, dropping the sex category entirely Score used at diagnosis Score should be reassessed at least annually, as risk is dynamic Latest Updates (2023–Present)
The 2023 ACC/AHA/ACCP/HRS AF Guideline allows use of other validated risk scores (ATRIA, GARFIELD-AF) alongside CHA2DS2-VASc, particularly for patients at intermediate risk where the anticoagulation decision is genuinely uncertain.
The guideline introduced the concept of stroke risk modifiers — AF burden, blood pressure control, and other dynamic factors — for patients with an annual risk below 2%.
The 2024 ESC AF Guideline formally adopted CHA2DS2-VA (maximum 8 points), removing sex category, on the evidence that women’s excess stroke risk is not evident until other risk factors are present. Studies show that applying the lower ACC/AHA hypertension thresholds causes “up-scoring” of CHA2DS2-VASc, reclassifying many patients into the anticoagulation-eligible category — a recognised limitation of a score built on binary comorbidity definitions (JAMA Cardiology 2023).
There is an ongoing move toward biomarker-enhanced scores such as the ABC stroke score (age, biomarkers — NT-proBNP and hs-cTnT — and clinical history), which outperform CHA2DS2-VASc in trial cohorts but have shown limited advantage in real-world elderly populations.
Examiner’s Tip — Mark-Earning Lines
“Congestive failure 1, Hypertension 1, Age ≥75 = 2, Diabetes 1, Stroke/TIA = 2, Vascular disease 1, Age 65–74 = 1, Sex (female) 1.”
“Maximum score is 9, not 10 — because age scores either 1 or 2, never both.”
“Anticoagulate at ≥2 in men, ≥3 in women (Class I).”
“Age ≥75 alone scores 2 — so every older patient with AF qualifies for anticoagulation.” “The score assesses stroke risk only and must always be paired with a bleeding risk score.” “It omits renal function, frailty, anaemia and AF burden, and has poor discrimination within the elderly.” “The 2024 ESC guideline moved to CHA2DS2-VA, removing sex category.”
How was your recall?
Rating marks the question complete. “Need another pass” also adds it to your bookmarks.
References
- PAPERS-2-3-4_COMBINED.pdf — page 1607
- GeriQBank source PDF — p. 1607
Spotted an error or something out of date?Report a problem with this page